Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 54

Related Articles by Review for PubMed (Select 20979469)

1.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ.

N Engl J Med. 2010 Oct 28;363(18):1693-703. doi: 10.1056/NEJMoa1006448. Erratum in: N Engl J Med. 2011 Feb 10;364(6):588.

2.

ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.

Casaluce F, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F, Gridelli C.

Target Oncol. 2013 Mar;8(1):55-67. doi: 10.1007/s11523-012-0250-9. Epub 2013 Jan 17. Review.

PMID:
23325296
3.

Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

Rodig SJ, Shapiro GI.

Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90. Review.

PMID:
21154129
4.

Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects.

Okamoto I, Nakagawa K.

Cancer Sci. 2012 Aug;103(8):1391-6. doi: 10.1111/j.1349-7006.2012.02327.x. Epub 2012 Jun 17. Review.

PMID:
22568572
5.

Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.

O'Bryant CL, Wenger SD, Kim M, Thompson LA.

Ann Pharmacother. 2013 Feb;47(2):189-97. doi: 10.1345/aph.1R002. Epub 2013 Feb 5. Review.

PMID:
23386065
6.

ALK inhibitors in the treatment of advanced NSCLC.

Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.

Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7. Review.

PMID:
23931927
8.

Crizotinib for the treatment of patients with advanced non-small cell lung cancer.

Bowles DW, Weickhardt AJ, Doebele RC, Camidge DR, Jimeno A.

Drugs Today (Barc). 2012 Apr;48(4):271-82. doi: 10.1358/dot.2012.48.4.1769835. Review.

PMID:
22536569
9.

Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.

Frampton JE.

Drugs. 2013 Dec;73(18):2031-51. doi: 10.1007/s40265-013-0142-z. Review.

PMID:
24288180
10.

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.

Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ.

Oncologist. 2012;17(11):1351-75. doi: 10.1634/theoncologist.2012-0311. Epub 2012 Sep 18. Review.

11.

Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.

Tiseo M, Gelsomino F, Bartolotti M, Bordi P, Bersanelli M, Rossi G, Ardizzoni A.

Expert Rev Anticancer Ther. 2011 Nov;11(11):1677-87. doi: 10.1586/era.11.157. Review.

PMID:
22050016
12.

Targeting anaplastic lymphoma kinase in lung cancer.

Shaw AT, Solomon B.

Clin Cancer Res. 2011 Apr 15;17(8):2081-6. doi: 10.1158/1078-0432.CCR-10-1591. Epub 2011 Feb 2. Review.

13.

Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.

Perez CA, Velez M, Raez LE, Santos ES.

Lung Cancer. 2014 May;84(2):110-5. doi: 10.1016/j.lungcan.2014.02.001. Epub 2014 Feb 8. Review.

PMID:
24598368
14.

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations.

Thunnissen E, Bubendorf L, Dietel M, Elmberger G, Kerr K, Lopez-Rios F, Moch H, Olszewski W, Pauwels P, Penault-Llorca F, Rossi G.

Virchows Arch. 2012 Sep;461(3):245-57. doi: 10.1007/s00428-012-1281-4. Epub 2012 Jul 24. Review.

15.

Crizotinib in the treatment of non--small-cell lung cancer.

Rothschild SI, Gautschi O.

Clin Lung Cancer. 2013 Sep;14(5):473-80. doi: 10.1016/j.cllc.2013.04.006. Epub 2013 Jun 20. Review.

PMID:
23790969
16.

Treatment and detection of ALK-rearranged NSCLC.

Peters S, Taron M, Bubendorf L, Blackhall F, Stahel R.

Lung Cancer. 2013 Aug;81(2):145-54. doi: 10.1016/j.lungcan.2013.03.017. Epub 2013 Jun 12. Review.

PMID:
23769207
17.

The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation.

Pillai RN, Ramalingam SS.

Curr Oncol Rep. 2012 Apr;14(2):105-10. doi: 10.1007/s11912-012-0213-4. Review.

PMID:
22311682
18.

Inhibitors of the anaplastic lymphoma kinase.

Mologni L.

Expert Opin Investig Drugs. 2012 Jul;21(7):985-94. doi: 10.1517/13543784.2012.690031. Epub 2012 May 22. Review.

PMID:
22612599
19.

ALK in lung cancer: past, present, and future.

Shaw AT, Engelman JA.

J Clin Oncol. 2013 Mar 10;31(8):1105-11. doi: 10.1200/JCO.2012.44.5353. Epub 2013 Feb 11. Review.

20.

Crizotinib.

Heigener DF, Reck M.

Recent Results Cancer Res. 2014;201:197-205. doi: 10.1007/978-3-642-54490-3_11. Review.

PMID:
24756793
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk